Study 207 demonstrated that VDPHL01, an oral extended-release minoxidil, produced rapid, robust, and visible hair regrowth in women with pattern hair loss, with nearly 90% reporting improvement and a favorable safety profile. The results position VDPHL01 as a potential first FDA-approved oral treatment for this large, underserved population.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.